Adjuvant chemotherapy for luminal A breast cancer: a prospective study comparing two popular chemotherapy regimens

被引:6
|
作者
Kader, Yasser Abdel [1 ]
El-Nahas, Tamer [1 ]
Sakr, Amr [1 ]
机构
[1] Cairo Univ, Dept Clin Oncol, Cairo, Egypt
来源
ONCOTARGETS AND THERAPY | 2013年 / 6卷
关键词
taxane; epirubicin; adjuvant; breast cancer; DOCETAXEL; PACLITAXEL; BENEFIT; TAXANES;
D O I
10.2147/OTT.S48397
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Introduction: Based on the variable benefit of taxanes in the adjuvant setting of early breast cancer in certain tumor phenotypes, especially in human epidermal growth factor receptor (HER) 2-positive and triple-negative disease, and with the observation of a lesser benefit in luminal A, this research article aimed at exploring the value of docetaxel in patients with an estrogen receptor-positive, HER2-negative disease phenotype, who might not derive the same benefits as those with other phenotypes. Patients and methods: This was a randomized prospective study comparing disease-free survival (DFS) and safety profile of sequential adjuvant three cycles Fluorouracil, Epirubicin, Cyclophosphamide followed by three cycles Docetaxel (FEC-D) versus six cycles classic Fluorouracil, Epirubicin, Cyclophosphamide (FEC)-100 in 60 Egyptian women who presented to Dar Al Fouad Hospital during the period June 2007 to July 2008 with (pT1-2 pN0-3 M0). The primary end point was DFS in a follow-up period of 4 years. The secondary end point was toxicity profile. Results: Four-year DFS rates were comparable in both arms: 73.3% +/- 8.1% in the FEC-D arm versus 76.5% +/- 7.8% in the FEC-100 arm (P = 0.83). N3 and grade III subgroups achieved the worst DFS in both subgroups (P = 0.001 and P = 0.214, respectively). The rate of nausea and vomiting was higher in the FEC-100 arm (P = 0.49), while grade III-IV neutropenia and febrile neutropenia incidence was similar between both arms. Conclusion: Sequential adjuvant chemotherapy with FEC followed by docetaxel achieved comparable DFS results to FEC alone in luminal A phenotype subgroups of breast cancer.
引用
收藏
页码:1073 / 1077
页数:5
相关论文
共 50 条
  • [1] Relative benefits of newer adjuvant chemotherapy regimens in luminal breast cancer subtypes
    Hart, Christopher D.
    Di Leo, Angelo
    BREAST, 2016, 27 : 189 - 189
  • [2] Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens
    E. E. Habib
    E. S. Fahmy
    Clinical and Translational Oncology, 2013, 15 : 965 - 968
  • [3] Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens
    Habib, E. E.
    Fahmy, E. S.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2013, 15 (11): : 965 - 968
  • [4] Is Adjuvant Chemotherapy Useful for Women With Luminal A Breast Cancer?
    Coates, Alan S.
    Colleoni, Marco
    Goldhirsch, Aron
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (12) : 1260 - 1263
  • [5] Adjuvant chemotherapy in luminal breast cancers
    Lim, Elgene
    Winer, Eric P.
    BREAST, 2011, 20 : S128 - S131
  • [6] Is adjuvant chemotherapy necessary for Luminal A-like breast cancer?
    Taskaynatan, Halil
    Kucukzeybek, Yuksel
    Alacacioglu, Ahmet
    Yildiz, Yasar
    Salman, Tarik
    Oflazoglu, Utku
    Varol, Umut
    Kucukzeybek, Betul Bolat
    Atahan, Murat Kemal
    Tarhan, Mustafa Oktay
    JOURNAL OF BUON, 2018, 23 (04): : 877 - 882
  • [7] The role of adjuvant chemotherapy in luminal B breast cancer.
    Zhao, Meng
    Zhang, Jianying
    Laubacher, Janette S.
    Ramirez, Maria-Teresa
    Shapiro, Charles L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)
  • [8] Locoregional response to neoadjuvant chemotherapy in operable breast cancer (BC). A prospective trial comparing two FEC regimens
    Ribeiro, RA
    Souza, CLP
    Santos, JFF
    Santos, CC
    Freitas, HC
    Campos, MC
    Machado, FH
    Juacaba, SF
    17TH INTERNATIONAL CANCER CONGRESS, VOL 1 AND 2, 1998, : 795 - 798
  • [9] Different adjuvant chemotherapy regimens in older breast cancer patients?
    Wildiers, H.
    Brain, E.
    ANNALS OF ONCOLOGY, 2015, 26 (04) : 613 - 615
  • [10] Benefit of Adjuvant Chemotherapy in Luminal A Breast Cancers
    Heneghan, H. M.
    McDermott, A.
    Malone, C.
    McLaughlin, R.
    Sweeney, K. J.
    Kerin, M. J.
    CANCER RESEARCH, 2010, 70